High Levels of the PSA (Prostate Specific Antigen) In Patients with Benign Prostatic Hyperplasia and Prostate CancerRishu BansaliMedPub
the magnetic resonance (MR) and MR spectroscopic imaging features of high-grade prostatic intraepithelial neoplasia (HGPIN) in patients with prostate cancer. ... JJ Hom,FV Coakley,JP Simko,... - 《Radiology》 被引量: 133发表: 2007年 Prostate cancer diagnosis among men with isolated high-grade...
Thus, if the initial PSA reading is about 10 ng/mL and it rises rapidly year on year, this can point to early-stage prostate cancer. Most research indicates that an increase of 0.75 ng/mL a year is an early indicator of prostate cancer if a man has a total PSA result between 4.0 ...
aMonitoring with PSA after treatment for prostate cancer is a mainstay of clinical practice, although the clinical utility of PSA is variable and depends on the disease stage of the indi-vidual patient. As has recently been observed, the lack of high quality information and paucity of clinical...
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival than bicalutamide (BIC)-ADT. Accordin...
prostate-specific antigen (PSA), and the severity in TCGA dataset. To assess the potential association between target gene expression levels and prostate cancer survival, we applied the non-parametric statistic Kaplan–Meier estimator and tested 162 stage 1 patients in TCGA data and 79 patients from...
with precipitous decline in PSA [prostate-specific antigen] levels down to undetectable and with disappearance of all cancer-derived ct [circulating tumor] DNA mutations in liquid biopsies. These patients had been rapidly progressing prior to pembrolizumab treatment and had exhausted almost all therapeuti...
(2012) Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. ... C Li,L Xu,X Lin,... - 《Medicine》 被引量: 0发表: 2021年 Statin use and fatal prostate cancer BACKGROUND:Statins are some of the ...
PSA and PSA velocity (PSAV, rate of PSA change over time) are biomarkers for diagnosis and prognosis of prostate cancer. Men who are at high risk for prostate cancer also have associated comorbidities for which they are taking NSAIDs and statins for long periods; therefore, it is important ...
The PSA doubling time was less than 3 months for 25.8% of patients and between 3 and 9 months for 74.2% of patients. The median time between radical prostatectomy and baseline was 4.4 years. Overall, 84.7% of patients had prior radiation and 42.35% of patients had prior ADT. "The ...